As cilia cannot effectively move in a thick, viscous environment, mucociliary clearance is deficient and a buildup of mucus occurs, clogging small airways. The accumulation of more viscous, nutrient-rich mucus in the lungs allows bacteria to hide from the bodys immune system, causing repeated respiratory infections. The presence of the same CFTR proteins in the pancreatic duct and sweat glands in the skin also cause symptoms in these systems. Chronic infections
The lungs of individuals with cystic fibrosis are colonized and infected by bacteria from an early age. These bacteria, which often spread among individuals with CF, thrive in the altered mucus, which collects in the small airways of the lungs. This mucus leads to the formation of bacterial microenvironments known as biofilms that are difficult for immune cells and antibiotics to penetrate. Viscous secretions and persistent respiratory infections repeatedly damage the lung by gradually remodeling the airways, which makes infection even more difficult to eradicate. The natural history of CF lung infections and airway remodeling is poorly understood, largely due to the immense spatial and temporal heterogeneity both within and between the microbiomes of CF patients.Over time, both the types of bacteria and their individual characteristics change in individuals with CF. In the initial stage, common bacteria such as S. aureus and H. influenzae colonize and infect the lungs. Eventually, Pseudomonas aeruginosa (and sometimes Burkholderia cepacia) dominates. By 18 years of age, 80% of patients with classic CF harbor P. aeruginosa, and 3.5% harbor B. cepacia.
A more thorough categorization of lupus includes the following types:
acute cutaneous lupus erythematosus
subacute cutaneous lupus erythematosus
discoid lupus erythematosus (chronic cutaneous)
childhood discoid lupus erythematosus
generalized discoid lupus erythematosus
localized discoid lupus erythematosus
chilblain lupus erythematosus (Hutchinson)
lupus erythematosus-lichen planus overlap syndrome
lupus erythematosus panniculitis (lupus erythematosus profundus)
tumid lupus erythematosus
verrucous lupus erythematosus (hypertrophic lupus erythematosus)
cutaneous lupus mucinosis
complement deficiency syndromes
drug-induced lupus erythematosus
neonatal lupus erythematosus
systemic lupus erythematosus

Treatment
There is still no cure for lupus but there are options to help control symptoms. The goal for treatment is to prevent flare ups and reduce organ damage. Doctors may prescribe a handful of different medications to help with their patients symptoms.Some medications are:

Nonsteroidal anti-inflammatory drugs (NSAIDs). Corticosteroids
Antimalarial drugs
BLyS-specific inhibitors
Immunosuppressive agents/chemotherapyAfter being diagnosed some treatment options that may be offered are:

Treatment consists primarily of immunosuppressive drugs (e.g., hydroxychloroquine and corticosteroids). A second-line drug is methotrexate in its low-dose schedule. In 2011, the U.S. Food and Drug Administration (FDA) approved the first new drug for lupus in more than 50 years to be used in the US, belimumab. In addition to medical therapy, cognitive behavioral therapy has also been demonstrated to be effective in reducing stress, anxiety, and depression due to the psychological and social impacts that lupus may have.People with SLE treated with standard care experience a higher risk of opportunistic infections and death than the general population. This risk is higher in men and in African Americans. Epidemiology
Worldwide
An estimated 5 million people worldwide have some form of lupus disease. 70% of lupus cases diagnosed are systemic lupus erythematosus.